---
title: "Barclays Reaffirms Their Buy Rating on Legend Biotech (LEGN)"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/286227290.md"
description: "Barclays analyst Etzer Darout has reaffirmed a Buy rating on Legend Biotech (LEGN) with a price target of $80.00. Darout, a 5-star analyst with a 26.4% average return, also covers other healthcare stocks. Additionally, H.C. Wainwright's Mitchell Kapoor issued a Buy rating for Legend Biotech, while TD Cowen maintained a Hold rating on the same stock."
datetime: "2026-05-13T08:55:42.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/286227290.md)
  - [en](https://longbridge.com/en/news/286227290.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/286227290.md)
---

# Barclays Reaffirms Their Buy Rating on Legend Biotech (LEGN)

Barclays analyst Etzer Darout maintained a Buy rating on Legend Biotech today and set a price target of $80.00.

### Claim 55% Off TipRanks

-   Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
-   Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks

According to TipRanks, Darout is a 5-star analyst with an average return of 26.4% and a 56.04% success rate. Darout covers the Healthcare sector, focusing on stocks such as Incyte, Legend Biotech, and Jazz Pharmaceuticals.

In addition to Barclays, Legend Biotech also received a Buy from H.C. Wainwright’s Mitchell Kapoor in a report issued yesterday. However, on the same day, TD Cowen maintained a Hold rating on Legend Biotech (NASDAQ: LEGN).

### Related Stocks

- [LEGN.US](https://longbridge.com/en/quote/LEGN.US.md)
- [XBI.US](https://longbridge.com/en/quote/XBI.US.md)
- [VHT.US](https://longbridge.com/en/quote/VHT.US.md)
- [PBE.US](https://longbridge.com/en/quote/PBE.US.md)
- [IBBQ.US](https://longbridge.com/en/quote/IBBQ.US.md)
- [BBH.US](https://longbridge.com/en/quote/BBH.US.md)
- [IBB.US](https://longbridge.com/en/quote/IBB.US.md)
- [LABU.US](https://longbridge.com/en/quote/LABU.US.md)
- [BCS.US](https://longbridge.com/en/quote/BCS.US.md)
- [BARC.UK](https://longbridge.com/en/quote/BARC.UK.md)
- [INCY.US](https://longbridge.com/en/quote/INCY.US.md)
- [JAZZ.US](https://longbridge.com/en/quote/JAZZ.US.md)
- [TD.US](https://longbridge.com/en/quote/TD.US.md)

## Related News & Research

- [These Analysts Revise Their Forecasts On Legend Biotech After Q1 Results](https://longbridge.com/en/news/286301750.md)
- [Legend Biotech Q1 Solid for Carvykti, Focus Shifts to In Vivo Pipeline, RBC Says](https://longbridge.com/en/news/286290495.md)
- [Roth MKM Sticks to Their Buy Rating for Capricor Therapeutics (CAPR)](https://longbridge.com/en/news/286497683.md)
- [Leerink Partners Sticks to Their Buy Rating for Ibio (IBIO)](https://longbridge.com/en/news/286588262.md)
- [Analyst Reiterates Buy on Corbus, Maintains $38 Price Target on CRB-701 Oncology Potential](https://longbridge.com/en/news/286284525.md)